CAS 1234423-95-0
:17-[[[3-[(4S)-6,8-Dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl]phenyl]sulfonyl]amino]-N-[2-[2-[2-[[[3-[(4S)-6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl]phenyl]sulfonyl]amino]ethoxy]ethoxy]ethyl]-8-oxo-12,15-dioxa-2,7,9-triazaheptadecanamide
Description:
The chemical substance with the name "17-[[[3-[(4S)-6,8-Dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl]phenyl]sulfonyl]amino]-N-[2-[2-[2-[[[3-[(4S)-6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl]phenyl]sulfonyl]amino]ethoxy]ethoxy]ethyl]-8-oxo-12,15-dioxa-2,7,9-triazaheptadecanamide" and CAS number "1234423-95-0" is a complex organic compound characterized by its intricate molecular structure, which includes multiple functional groups such as sulfonamides, amides, and oxo groups. The presence of dichloro and tetrahydroisoquinoline moieties suggests potential biological activity, possibly as a pharmaceutical agent. Its long carbon chain and multiple ether linkages indicate a degree of hydrophilicity, which may influence its solubility and bioavailability. The compound's structural complexity may also suggest specific interactions with biological targets, making it of interest in medicinal chemistry. However, detailed studies would be necessary to elucidate its properties, including stability, reactivity, and potential therapeutic applications.
Formula:C50H66Cl4N8O10S2
InChI:InChI=1S/C50H66Cl4N8O10S2/c1-61-31-43(41-27-37(51)29-47(53)45(41)33-61)35-7-5-9-39(25-35)73(65,66)59-15-19-71-23-21-69-17-13-57-49(63)55-11-3-4-12-56-50(64)58-14-18-70-22-24-72-20-16-60-74(67,68)40-10-6-8-36(26-40)44-32-62(2)34-46-42(44)28-38(52)30-48(46)54/h5-10,25-30,43-44,59-60H,3-4,11-24,31-34H2,1-2H3,(H2,55,57,63)(H2,56,58,64)/t43-,44-/m0/s1
InChI key:InChIKey=DNHPDWGIXIMXSA-CXNSMIOJSA-N
SMILES:ClC1=C2C([C@@H](CN(C)C2)C3=CC(S(NCCOCCOCCNC(NCCCCNC(NCCOCCOCCNS(=O)(=O)C4=CC(=CC=C4)[C@H]5C=6C(=C(Cl)C=C(Cl)C6)CN(C)C5)=O)=O)(=O)=O)=CC=C3)=CC(Cl)=C1
Synonyms:- 17-[[[3-[(4S)-6,8-Dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl]phenyl]sulfonyl]amino]-N-[2-[2-[2-[[[3-[(4S)-6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl]phenyl]sulfonyl]amino]ethoxy]ethoxy]ethyl]-8-oxo-12,15-dioxa-2,7,9-triazaheptadecanamide
- Ibsrela
- AZD 1722
- Tenapanor
- 12,15-Dioxa-2,7,9-triazaheptadecanamide, 17-[[[3-[(4S)-6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl]phenyl]sulfonyl]amino]-N-[2-[2-[2-[[[3-[(4S)-6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl]phenyl]sulfonyl]amino]ethoxy]ethoxy]ethyl]-8-oxo-
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 5 products.
Tenapanor
CAS:Tenapanor (RDX 5791), an NHE3 inhibitor, regulates sodium in the gut and kidney with a strong preclinical safety record and minimal side effects.Formula:C50H66Cl4N8O10S2Purity:99.49% - 99.85%Color and Shape:SolidMolecular weight:1145.05Tenapanor
CAS:<p>Tenapanor is a novel antidiabetic drug that has been shown to be effective in the treatment of type 2 diabetes. Tenapanor (INN) reduces blood glucose levels by stimulating insulin release from pancreatic beta-cells and increasing insulin sensitivity in peripheral tissues. Tenapanor binds to the ATP-binding site of the phosphoinositide 3-kinase-related protein kinase 1 (PI3K1) enzyme, which is involved in glucose metabolism. It also inhibits phosphodiesterase 4D (PDE4D), an enzyme that degrades cyclic adenosine monophosphate (cAMP). This dual mechanism of action leads to increased insulin secretion and increased insulin sensitivity, which results in improved glycemic control.<br>Tenapanor has also been shown to improve long-term efficacy and reduce hypoglycemia when used as a pharmacological treatment for type 2 diabetes. The agent binds to ATP-binding sites on PI3K1, which prevents its</p>Formula:C50H66Cl4N8O10S2Purity:Min. 95%Molecular weight:1,145.04 g/molTenapanor (Butylene-D8)
CAS:Controlled ProductFormula:C50D8H58Cl4N8O10S2Color and Shape:NeatMolecular weight:1153.098Tenapanor
CAS:Controlled ProductFormula:C50H66Cl4N8O10S2Color and Shape:NeatMolecular weight:1145.049



